4 completed, 2 unknown, 1 active not recruiting, 1 recruiting. 4 Phase 2, 3 Phase 1, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Recruiting 1, Unknown 1 |
| Phase 1 | 3 | Completed 2, Active not recruiting 1 |
| Early Phase 1 | 1 | Unknown 1 |
Follow Gray Zone Lymphoma: new trials by email Literature Review of Gray Zone Lymphoma trials Research Report on Gray Zone Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Amping up With PemJAK Ruxolitinib, Pembrolizumab - Non-Hodgkin Lymphoma, Hodgkin Disease Lymphoma | Phase 2 | Recruiting | Seda S. Tolu | 53 | 2025-12-03 | 2025-12-16 |
| An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma Anti CD30 CAR-T Cell Injection - Hodgkin Lymphoma, NK/T Cell Lymphoma | Early Phase 1 | Unknown | Zhejiang University | 9 | 2022-02-10 | 2022-01-26 |
| A Prospective Study of PD-1 Inhibitor Combined With ICE in the Treatment of Relapsed/Refractory Gray Area Lymphoma PD-1 inhibitor +ICE - Gray Zone Lymphoma, Relapse/Recurrence | Phase 2 | Unknown | Zhejiang Cancer Hospital | 20 | 2021-05-01 | 2021-04-27 |
| Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL ATLCAR.CD30.CCR4 cells, ALTCAR.CD30 cells, Bendamustine - Lymphoma, Immune System Diseases | Phase 1 | Active not recruiting | UNC Lineberger Comprehensive Cancer Center | 43 | 2018-10-29 | 2026-06-12 |
| Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine Bendamustine, Cyclophosphamide - Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia | Phase 1 | Completed | University of Arizona | 50 | 2016-11-29 | 2025-11-10 |
| Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma CPX-351 - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 1 | Completed | Children's Hospital Medical Center, Cincinnati | 27 | 2013-09-01 | 2020-11-09 |
| Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma Everolimus, Rituximab - CD20+, B-cell Lymphomas, Mantle Cell Lymphoma | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 56 | 2012-09-01 | 2021-10-26 |
| Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma Etoposide, Rituximab, Prednisone - Diffuse Large B-Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 348 | 1993-05-08 | 2025-06-22 |
Hodgkin Disease (4) · Burkitt Lymphoma (3) · Lymphoma (3) · Lymphoma, Large B-Cell, Diffuse (3) · Lymphoma, Large-Cell, Anaplastic (3) · Leukemia (2) · Leukemia, Myeloid, Acute (2) · Lymphoma, Mantle-Cell (2) · Lymphoma, Non-Hodgkin (2) · Lymphoma, T-Cell, Cutaneous (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Dendritic Cell Sarcoma, Interdigitating (1) · Immune System Diseases (1) · Immunoblastic Lymphadenopathy (1) · Immunoproliferative Disorders (1)
Hemic and Lymphatic Diseases (7) · Neoplasms by Histologic Type (7) · Immune System Diseases (6) · Immunoproliferative Disorders (6) · Lymphatic Diseases (6) · Lymphoproliferative Disorders (6) · Neoplasms (6) · Lymphoma, Non-Hodgkin (5) · Lymphoma (4) · Lymphoma, B-Cell (4) · Lymphoma, T-Cell (4) · DNA Virus Infections (3) · Epstein-Barr Virus Infections (3) · Herpesviridae Infections (3) · Infections (3)
Bendamustine Hydrochloride (2) · Cyclophosphamide (2) · Etoposide (2) · Rituximab (2) · Biopsy (1) · CPX-351 (1) · Carboplatin (1) · Dioctyl Sulfosuccinic Acid (1) · Doxorubicin (1) · Everolimus (1) · Lactulose (1) · Laparotomy (1) · Magnetic Resonance Imaging (1) · Omeprazole (1) · Ondansetron (1)
Children's Hospital Medical Center, Cincinnati (1) · National Cancer Institute (NCI) (1) · Seda S. Tolu (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · UNC Lineberger Comprehensive Cancer Center (1) · University of Arizona (1) · Zhejiang Cancer Hospital (1) · Zhejiang University (1)
United States (6) · China (1)
Cong Li (1) · Douglas Gladstone, MD (1) · Emmanuel Katsanis, MD (1) · Huang He, PhD (1) · John Perentesis, MD (1) · Mark J Roschewski, M.D. (1) · Natalie Grover, MD (1) · Seda Tolu, MD (1)
PMID 23574119, PMID 24224624, PMID 25024303, PMID 29234922, PMID 29748435, PMID 29908231, PMID 30125215, PMID 32582591, PMID 34432874, PMID 35460929, PMID 35847727, PMID 35882475, PMID 40270968
R01CA247497 (1)